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Abstract
An important objective in environmental risk assessment is estimation of minimum exposure lev-
els, called Benchmark Doses (BMDs) that induce a pre-specified Benchmark Response (BMR) in
a target population. Established inferential approaches for BMD analysis typically involve one-
sided, frequentist confidence limits, leading in practice to what are called Benchmark Dose Lower
Limits (BMDLs). Appeal to Bayesian modeling and credible limits for building BMDLs is far
less developed, however. Indeed, for the few existing forms of Bayesian BMDs, informative prior
information is seldom incorporated. We develop reparameterized quantal-response models that ex-
plicitly describe the BMD as a target parameter. Our goal is to obtain an improved estimation and
calculation archetype for the BMD and for the BMDL, by employing quantifiable prior belief to
represent parameter uncertainty in the statistical model. Implementation is facilitated via a Monte
Carlo-based adaptive Metropolis (AM) algorithm to approximate the posterior distribution. An
example from environmental carcinogenicity testing illustrates the calculations.
Keywords: Adaptive Metropolis sampling, Bayesian modeling, Benchmark analysis, Dose-response
analysis, Prior elicitation, Quantitative risk assessment.
1 Introduction
1.1 Benchmark Risk Analysis
A primary objective in environmental risk assessment is characterization of the severity and
likelihood of adverse outcomes caused by a hazardous agent (Stern, 2008). The outcome could
be death, cancer, mutation, damage caused by environmental or ecological hazards, etc. In this
context, the risk function, R(d), is defined as the probability of exhibiting the adverse effect in
a subject, object, or system exposed to a particular dose level, d, of the hazardous agent. To
illustrate, consider the following example.
Example 1. Benchmarking mammalian carcinogenicity of cumene.
Cumene, the colloquial name for isopropylbenzene (C9H12), is a hydrocarbon solvent employed in
the production of industrial compounds such as phenol and acetone. Occupational and industrial
exposures to cumene are common, so the U.S. National Toxicology Program (NTP) explored various
forms of mammalian toxicity to the chemical (U.S. NTP, 2009). For example, Table 1 displays
quantal-response data on induction of lung tumors (alveolar/bronchiolar adenomas and carcinomas)
by cumene in laboratory mice after chronic, two-year, inhalation exposure.
In the table, a clear dose response is evidenced. Of additional interest, however, is characteriza-
tion of the effects at ‘low-dose’ exposures, in order to inform risk characterization of this potential
carcinogen. We return to these data below.
A contemporary approach to quantal-response risk estimation is known as benchmark analysis.
First introduced by Crump (1984), the method uses an assumed functional specification for R(d) to
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Table 1: Quantal carcinogenicity data: Alveolar/bronchiolar adenomas and carcinomas in female
B6C3F1 mice after two-year inhalation exposure to cumene (C9H12). Source: U.S. NTP (2009).
Exposure conc. (ppm), di 0 125 250 500
Animals with tumors, Yi 4 31 42 46
Animals tested, Ni 50 50 50 50
provide low-dose estimates for the risk. When applied in environmental or public health settings,
however, adjustments are made for background or spontaneous effects. Since R(0) represents the
background response for all subjects in a population, the risk function is re-expressed in terms of
an excess-above-background response rate (Piegorsch and Bailer, 2005, §4.2.1). With quantal data,
the extra risk function RE(d) = {R(d) − R(0)}/{1 − R(0)} is typically employed. From this, the
benchmark dose (BMD) is calculated by inverting RE(d) at a predetermined level of risk; the latter
is called the benchmark risk or benchmark response (BMR). In effect, we solve RE(BMD) = BMR
∈ (0, 1); BMRs between 0.01 and 0.10 are most often seen in practice (U.S. EPA, 2012).
Statistical inferences in benchmark analysis focus on 100(1−α)% confidence (or credible) limits
for the BMD. Driven by public health or other safety considerations, only one-sided, lower limits
are targeted, denoted as BMDLs (Crump, 1995). Where needed for clarity, we add a subscript
for the BMR level at which each quantity is calculated: BMD100BMR and BMDL100BMR. In this
fashion, use of BMDs and BMDLs for quantifying and managing risk with a variety of endpoints is
growing in both the United States and the European Union (U.S. General Accounting Office, 2001;
European Union, 2003; OECD, 2006, 2008).
1.2 Parametric Bayesian Benchmark Analysis
With quantal data such as those in Table 1, we take Yi as the number of responses at the i
th
dose level, out of Ni subjects tested at that dose (i = 1, ...,m). The standard statistical model here
is the binomial, i.e., Yi ∼ indep. Bin
(
Ni, R(di)
)
, where R(di) is the risk at dose di. For generic
purposes, we denote θ as an unknown parameter vector that describes R(d).
In risk-analytic studies with quantal data, estimation of the BMD has traditionally been per-
formed via maximum likelihood (Piegorsch and Bailer, 2005, §4.3.1), producing maximum likeli-
hood estimators (MLEs) θ̂, with corresponding MLEs R̂(d) for R(d) and R̂E(d) for RE(d). Setting
R̂E(d) = BMR and solving for d yields the MLE, B̂MD100BMR. The corresponding, frequentist
BMDL is built from the statistical properties of B̂MD.
Appeal to Bayesian modeling and credible limits for building BMDLs is far less developed.
For quantal-response data, Naufal et al. (2009) studied hierarchical dose-response models under a
suite of forms available from the U.S. Environmental Protection Agency’s Benchmark Dose Soft-
ware, BMDS (Davis et al., 2012), including the well-known logistic and probit models: R(d) =
{1 + exp(−β0 − β1d)}
−1 and R(d) = Φ(β0 + β1d), respectively. [Here, Φ(z) is the standard nor-
mal cumulative distribution function.] They placed non-informative priors on the dose-response
parameters of each model. Shao and Small (2011) also studied the logistic model, along with the
quantal-linear model
R(d) = 1− exp(−β0 − β1d) (1.1)
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(where β0 ≥ 0 and β1 ≥ 0), a popular dose-response form in risk assessment (Buckley et al., 2009).
They similarly placed objective priors on the β-parameters; further developments appeared in
Shao and Small (2012). Shao (2012) expanded these considerations to the probit model, and also in-
troduced a power prior to build historical control information into the hierarchy. Wheeler and Bailer
(2012) presented semi-parametric Bayesian models for the dose response, incorporating a probit
kernel and cubic B-splines. They placed normal priors on the basis-function coefficients and built
dose-response monotonicity into their prior constraints. The normal priors were often flattened to
be essentially non-informative (or objective) although like Shao (2012), Wheeler and Bailer built in-
formative priors at d = 0 to incorporate potential historical control information. Guha et al. (2013)
described a nonparametric Bayesian model for the quantal setting, with beta/Dirichlet priors on
pertinent probabilities related to their nonparametric construction.
The Bayesian approach for BMD estimation has also been applied with non-quantal data, and
as in the quantal setting its use enjoys increasing application. See, e.g., Wheeler and Bailer (2009b),
Morales et al. (2006), Held (2004), or Coull et al. (2003).
Notably, previous methods for calculating parametric Bayesian BMDs typically assume objec-
tive (and sometimes improper) prior distributions for the unknown model parameters. For example,
in the logistic model mentioned above the β-parameters are interpreted as the usual regression in-
tercept and slope on a logit scale. With quantal data, at least, it is unusual for truly informative,
risk-analytic, prior knowledge to be available on parameters such as β0 and β1, since their interpre-
tation is so generic. Such a strategy neglects informative prior information that may be available
on the true quantity of interest in this setting, the BMD.
Of course, informative prior knowledge on the BMD may not always exist in practice, and in this
case objective priors serve a useful purpose. When such prior information is available, however, the
Bayesian paradigm can achieve its true potential. Herein, we explore this by reparameterizing the
quantal-response model to explicitly incorporate the BMD. Following on previous presentations for
parametric Bayesian benchmark modeling (Shao and Small, 2011, 2012), we focus on the popular
quantal-linear dose-response model in (1.1), due to its heavy use in environmental toxicology.
Section 2 describes our reparameterization strategy in greater detail. Section 3 develops a Bayesian
framework using the reparameterized quantal-linear form for R(d). Section 4 returns to the cumene
carcinogenicity data from Example 1, while Section 5 ends with a brief discussion.
2 The Quantal-Linear Dose-Response Model
2.1 Benchmark Analysis with the Quantal-Linear Model
The quantal-linear form R(d) = 1−e−β0−β1d from (1.1) is a popular construct for dose-response
modeling. Also known as the one-stage model or the complementary-log model, it is a special case
of the famous multistage model in carcinogenicity testing (Piegorsch and Bailer, 2005, §4.2.1). This
has led it to wide application in toxicological risk assessment with quantal data (Foronda et al.,
2007; Buckley et al., 2009; Shao and Small, 2012). Notice that R(0) = 1−e−β0 so that the quantal-
linear extra risk is simply RE(d) = 1 − e
−β1d. To find the BMD, we solve RE(BMD) = BMR to
obtain
BMD100BMR = −
log(1− BMR)
β1
. (2.1)
Recall that we require βj ≥ 0 (j = 0, 1) in (1.1). [In the exceptional setting where β1 = 0, no dose
effect is present. If so, the agent under study would be viewed as innocuous, consistent with the
corresponding ‘definition’ of BMD =∞ under (2.1).]
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2.2 Reparameterizing the Quantal Linear Model
For benchmark risk analysis, a risk assessor, toxicologist, or other domain expert may often have
prior knowledge about the target parameter, the BMD, and possibly also about other application-
specific values such as the risk at certain doses; cf. the use of control-response information for R(0)
by Shao (2012) and Wheeler and Bailer (2012). Our goal is to reparameterize R(d) in terms of
meaningful parameters whose prior distributions are more intuitive to elicit in practice. The repa-
rameterization strategy is, of course, not new, even in benchmark analysis; e.g., Parham and Portier
(2005, §14.3.4) re-expressed the quantal-linear model in terms of the BMD to facilitate construction
of frequentist BMDLs. Following on their lead, we reformulate the unknown regression parame-
ters in (1.1) in terms of well-understood risk-analytic quantities: the target value, BMD, and the
background risk, R(0). [The latter quantity is technically a nuisance parameter here, but it is
nonetheless likely to be associated with non-trivial prior information, e.g., from historical control
databases (Wheeler and Bailer, 2012).] For simplicity, denote these as ξ = BMD and γ0 = R(0),
respectively. Under (1.1), we know ξ = − log(1 − BMR)/β1 and γ0 = 1 − e
−β0 . [For convenience
in the sequel, we generally suppress the BMR subscript on ξ, although it is understood that the
BMD is dependent on the chosen level of BMR ∈ (0, 1).] With these, R(d) becomes:
R(d) = 1− exp
{
log(1− γ0) +
log(1− BMR)
ξ
d
}
. (2.2)
The corresponding extra risk is simply RE(d) = 1− (1−BMR)
d/ξ. While the notation may appear
more burdensome, explicit incorporation of the parameters ξ and γ0 allows us to formulate a clearer,
more application-oriented hierarchical model. We explore this further in the next section.
3 Bayesian Benchmark Analysis
3.1 Prior Specification
Under our reformulation the unknown parameter vector is θ = [ξ γ0]
T . To construct a Bayesian
hierarchy, we assign a joint p.d.f. to θ: π(θ) = π(ξ, γ0). Mimicking previous Bayesian models for
benchmark analysis (Shao and Small, 2011; Shao, 2012), we assume the unknown parameters enter
into the prior independently, so that π(ξ, γ0) = π(ξ)π(γ0). This assumption is not as arbitrary
as it may seem: to assess potential correlation between the two quantities, we accessed data from
a study (Nitcheva et al., 2007) of 91 different chemical carcinogens archived in the U.S. EPA’s
Integrated Risk Information System (IRIS: see http://www.epa.gov/iris). Each of the 91 IRIS
data sets represented a quantal dose-response to a particular carcinogen, allowing us to compute
(frequentist) ML estimates for both ξ and γ0 under (1.1). We then calculated the Spearman rank
correlation rS (Kvam and Vidakovic, 2007, §7.3) across the 91 pairs of MLEs (ξ̂, γ̂0). We found the
correlation to be insignificantly different from zero: rS = −0.039;P > 0.20.
To specify the individual components of the joint prior, we employ established, flexible forms.
For ξ we make an inverse gamma assumption: ξ ∼ IG(α, β) with marginal prior density π(ξ|α, β) =
βα
Γ(α)ξ
−(α+1)e−β/ξI(0,∞)(ξ), where Γ(a) is the usual gamma function and IA(x) is the indicator
function that returns 1 if x ∈ A and 0 otherwise. For γ0 = R(0) we take γ0 ∼ Beta(ψ, ω) with
marginal prior π(γ0|ψ, ω) =
Γ(ψ+ω)
Γ(ψ)Γ(ω)γ
ψ−1
0 (1− γ0)
ω−1I(0,1)(γ0). (Below, we examine how deviations
from these priors—emphasizing sensitivity to the inverse gamma assumption—affect the eventual
inferences on ξ.) Conceptually, this approach shares similarities with a Bayesian inverse dose
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estimation strategy suggested by Babb et al. (1998) for use in clinical trials; however, technical
differences exist between the two methods, driven primarily by dissimilarities between their medical-
safety application and our environmental-risk motivation.
The various hyperparameters, α, β, ψ, and ω, require specification for implementation of our
model. (One could also build further levels into the hierarchy by constructing hyperprior p.d.f.s,
and this has potential for future study. We do not investigate it here, however.) Our goal is
elicitation, to the best extent possible, of each marginal prior by incorporating the domain expert’s
prior knowledge.
A broad literature exists on how to conduct prior elicitation; see, e.g., O’Hagan et al. (2006)
or Kuhnert (2011) and the references therein. From it, we adopt the general strategy that domain
experts with minimal statistical expertise are best able to provide prior information in the form
of basic location summaries. Medians and other quartiles can be especially effective: based on
interactions with environmental toxicologists and risk assessment domain experts, we have found
that for the target parameter ξ, specification of the the median (Q2), along with the first/lower
quartile (Q1) of the IG prior is most effective. Put simply, prior expert knowledge for ξ is likely
to be more accurate closer to the origin, since BMDs are associated with adverse effects at low
doses. Similarly, for the beta prior on γ0 we also elicit the two quartiles Q1 and Q2. We then solve
for the pertinent hyper-parameters given these quartiles. (Details are provided in a Supplemental
Document.) Of course, other elicitation values are possible, and analysts may wish to experiment
with selection of other quartiles, terciles, percentiles, etc.
Given the resulting values of α, β, ψ, and ω, the joint prior for θ = [ξ γ0]
T is fully specified,
and we proceed with calculation of the posterior p.d.f. We describe this in the next subsection.
Before continuing, however, we acknowledge that cases can arise where the prior elicitation breaks
down, say, if prior experience with an environmental agent is so limited that the toxicologist simply
has no idea where the BMD will lie. When this occurs, moving to objective specifications for the
prior densities may be necessary. Many possibilities exist for building objective priors on a strictly
positive quantity such as ξ, and on a probability such as γ0. We favor a simple approach: for an
objective prior on ξ, use ξ ∼ IG(0.001, 0.001) [another option could be ξ ∼ Gamma(0.001, 0.001);
see below]. The IG prior is a popular suggestion in the literature for right-skewed, positive quantities
(Lambert et al., 2005; Christensen et al., 2011, §1.2), such as the BMD. One could alternatively
appeal to an (improper) objective prior of the form π(ξ) ∝ 1/ξ, a conventional choice that is often
recommended for positive parameters (O’Hagan, 1994, §9.17). In order to facilitate the posterior
computations, however, we prefer to employ proper prior densities. In fact, the IG(0.001, 0.001)
prior can approximate the improper reciprocal prior quite well when ξ is not extremely close to zero.
The Gamma(0.001, 0.001) can also serve as an approximator for 1/ξ, although for large dose values
the approximation can break down. Indeed, we find that scaling the doses to make the highest
dose equal 1 is a convenient device that allows both IG(0.001, 0.001) and Gamma(0.001, 0.001) to
approximate the conventional improper 1/ξ prior. As such, we perform our calculations with doses
scaled so that the maximum administered dose equals 1.
For an objective prior on γ0, we consider the univariate Jeffreys prior: γ0 ∼ Beta
(
1
2 ,
1
2
)
. This
assigns symmetrically high density to values of γ0 → 0 and γ0 → 1. The former is reasonable
in our toxicological setting, although the latter is problematic, since γ0 represents the probability
of an adverse response under no exposure and is usually small in risk-analytic applications. (A
similar complaint could be raised against use of a ‘vague’ uniform prior for γ0.) In the end, even
the valid-but-imprecise argument that low prior weight should be assigned to values of γ0 → 1 is
itself a form of subjective prior knowledge, and construction of truly objective priors for γ0 may
be difficult. As the background response rate in the subject organism under study, γ0 will be a
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well-understood quantity in practice, and as others have noted there will often be at least some
useful historical control information available for it. We expect that calls for objective priors on
γ0 in this setting will be rare. If in the extreme this is not the case, we default to the objective
Jeffreys prior γ0 ∼ Beta
(
1
2 ,
1
2
)
, although we recognize the enigmatic aspects of such a strategy.
3.2 Posterior Analysis via Stochastic Approximation
Given our prior specification from §3.1 under a binomial likelihood, the joint posterior p.d.f. for
θ = [ξ γ0]
T is
π(ξ, γ0|Y ) =
∏n
i=1
(Ni
Yi
)
R(di)
Yi{1 −R(di)}
Ni−Yi
m(Y )
βαe−β/ξ
Γ(α)ξα+1
Γ(ψ + ω)
Γ(ψ)Γ(ω)
γψ−10 (1− γ0)
ω−1 (3.1)
over ξ > 0 and γ0 > 0. The denominator of π(ξ, γ0|Y ) contains the marginal likelihood
m(Y ) =
∫ ∞
0
∫ 1
0
n∏
i=1
(
Ni
Yi
)
R(di)
Yi{1−R(di)}
Ni−Yiπ(ξ|α, β)π(γ0|ψ, ω)dγ0dξ,
which is intractable under our elicited prior structure. To evaluate (3.1) we therefore turn to Monte
Carlo posterior approximations using an adaptive Metropolis (AM) strategy (Andrieu and Thoms,
2008). This is detailed in the Supplementary Document.
For a given data ensemble (Y ,N ,d), we employ the AM algorithm to produce a bivariate
chain of draws, {ξk, γ0k}
K
k=1. For practical purposes, however, we first check the acceptability of
the data before employing the algorithm. Our experience shows that a shallow dose response can
create unstable frequentist ξˆ100BMR estimates, and very shallow responses may cause the model fit
to fail entirely. Indeed, the EPA’s BMDS software program will not estimate a BMD for a flat
or negatively trending dose response (Wheeler and Bailer, 2009a). For these reasons, we chose to
mark flat or decreasing-trend data as ‘data failures’ and not perform estimation for them (see the
Appendix).
We apply the AM algorithm to any data set passing our data-failure screen. We also include
a ‘burn-in’ diagnostic—detailed in the Supplementary Document—to ensure that the Monte Carlo
chain produces a stable approximation to the posterior distribution. If the diagnostic fails after
multiple generations of the AM chain, we consider this an ‘algorithm failure’ and do not report
values for the BMD or BMDL. (This is a rare occurrence. Again, see the Supplementary Document
for specifics.) The larger the value of K and the more stable the resulting chain, as determined
by the diagnostics mentioned above, the better the approximation. Our experience suggests that
a starting value of K = 100, 000, with reduction for burn-in to about 90,000 or 80,000 draws,
generally provides stable results. We derive inferences on ξ from this retained sample of draws.
3.3 Bayesian Estimation and Inference on the BMD
For estimating the BMD, we appeal to standard decision-theoretic principles and select the
Bayes estimator based on minimization of the Bayes risk, after specification of an underlying loss
function. As is well-known, choice of squared-error loss leads to the posterior mean, E[ξ|Y ], as
the Bayes estimator, while absolute-error loss leads to the posterior median (Casella and Berger,
2002, §7.3.4). We can approximate these posterior quantities using our Monte Carlo sample’s
arithmetic mean or median, respectively. If subject-matter considerations cannot guide the choice
of loss function, and thus which estimator to employ, appeal to absolute-error loss and the posterior
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median might be preferable. This suggestion is, admittedly, empirical: with small sample sizes we
generally find the (approximated) posterior for ξ to exhibit a right skew, and the median is more
robust against large skews. This has an important, practical consequence: note that a larger
estimated BMD implies a higher level of ‘acceptable’ exposure to a potential toxic agent. If this
estimated value is artificially inflated due to anomalies such as a heavy right skew, any public health
or environmental guidelines based on the estimate may be unnecessarily lax, and even unsafe. Using
the posterior median rather than the posterior mean in such a situation would represent a more-
precautionary course of action.
Alert readers may notice that from a decision-theoretic perspective, this issue of how to es-
timate the BMD begs a larger question: both the squared-error and absolute-error losses treat
deviations symmetrically. Should we employ an asymmetric loss function here instead? Arguably,
yes. In effect, a high BMD quantitatively views large exposures to a potentially hazardous agent as
relatively safe. If, in truth, the agent is highly toxic, the consequences of such a decision could be
severe from a public health or environmental safety perspective. This is more consequential than
incorrectly driving BMD → 0 and imposing strict exposure limitations on an innocuous or weakly
toxic agent. Unless (considerable, we would contend) socioeconomic factors can counterbalance
these safety concerns, BMD overestimation generates a greater ‘loss’.
Many asymmetric loss constructions are possible; we employ the simple bilinear loss function
of O’Hagan (1994, §2.46):
L(∆, ξ) =
{
a(ξ −∆) ∆ ≤ ξ
b(∆− ξ) ∆ > ξ
(3.2)
where ξ is the target quantity, estimated by the decision ∆. The constants a and b tune the bilinear
loss for each individual application. (When a = b we recover absolute-error loss.) Since we treat
overestimation of ξ more harshly than underestimation, we take b > a > 0. O’Hagan (1994) shows
that under (3.2), the optimal Bayes estimator for ξ is the 100
(
a
a+b
)
th percentile of the posterior
distribution π(ξ|Y ). As a default choice for benchmark dose estimation, we suggest setting the
ratio ab =
1
2 , i.e., overestimation of ξ incurs twice as much relative loss as underestimation. If so,
the optimal Bayesian estimator ξ̂100BMR becomes the lower/first tercile of π(ξ|Y ). We estimate this
with the lower tercile from our Monte Carlo sample of ξ.
For a Bayesian BMDL, say, ξ100BMR, we essentially desire a one-sided, lower, 100(1−α)% credible
limit on ξ, satisfying P (ξ > ξ100BMR|Y ) = 1 − α. At the traditional level of α = 0.05, this is the
lower 5th percentile of π(ξ|Y ), which we approximate via the lower 5th percentile from our Monte
Carlo chain.
3.4 Prior Sensitivity: ǫ-Contamination Analysis
To investigate the influence of our IG prior assumption on the eventual BMDL ξ100BMR, we
consider a prior sensitivity analysis. (One could also perform a sensitivity analysis of the beta
prior for γ0; however, since γ0 is an obvious nuisance parameter in terms of BMD estimation
and inference, we do not highlight that alternative here.) Our experiences with ξ for this model
show that the parameter uncertainty can almost always be described via a right-skew, which helps
motivate the IG prior specification. As mentioned above, however, an obvious alternative is the
traditional gamma distribution: ξ ∼ Gamma(α, β), where α and β are elicited using the same
expert opinion as detailed above.
We follow O’Hagan (1994, §7.15) and rewrite the prior density on ξ as a contaminated mixture
of IG and gamma priors. Treating the IG density as the base prior, π0(ξ), and the gamma as the
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contaminating density, q(ξ), the prior for ξ is written as
π(ξ) = (1− ǫ)π0(ξ) + ǫq(ξ), (3.3)
where ǫ ∈ [0, 1] controls the degree of prior contamination. When ǫ = 0, no contamination appears
and the prior for ξ is the base IG density; when ǫ = 1, the prior density function for ξ is completely
replaced by the contaminating gamma prior.
Employing the prior density in the ǫ-contamination form from (3.3), we denote ξ100BMR(ǫ) as
the estimated BMDL for a specific ǫ. We then monitor the evolution of ξ100BMR(ǫ) as ǫ increases
from 0 to 1.
An additional quantification of the ǫ-contaminating prior’s influence is the instantaneous rate of
change of the posterior inference at ǫ = 0 (O’Hagan, 1994, §7.15). We calculate this as the (absolute
value of the) first derivative of ξ100BMR(ǫ) at ǫ = 0: |D(q)| =
∣∣limǫ→0 1ǫ{ξ100BMR(ǫ)− ξ100BMR(0)}∣∣.
O’Hagan showed that D(q) simplifies to
D(q) =
{
ξ100BMR(1)− ξ100BMR(0)
} mq(Y )
m0(Y )
, (3.4)
where mq(Y ) and m0(Y ) are the marginal likelihoods under the contaminating gamma prior den-
sity, q(ξ), and base IG prior density, π0(ξ), respectively.
In order to calculate |D(q)|, values of ξ100BMR(1) and ξ100BMR(0) are obtained as the estimated
BMDLs using q(ξ) and π0(ξ), respectively. To find the marginal likelihoods, mq(Y ) and m0(Y ),
we appeal to our AM sample and employ a geometric estimator via the bridge sampling method
recommended by Meng and Wong (1996) and Lopes and West (2004). (Details are given in the
Supplementary Document.) |D(q)| can then be used as a measure of sensitivity: as it draws closer
to zero, the posterior inferences are less affected by the contaminating prior (O’Hagan, 1994, §7.15).
We apply |D(q)| as part of our larger Bayesian benchmark analysis. The next section illustrates
these various calculations.
3.5 Posterior Calculations on the Extra Risk Scale
Despite its moniker, the benchmark dose is critically related to the extra risk function RE(d).
As West et al. (2012) emphasized, the BMD and in particular the BMDL are used to indicate where
exposures to hazardous stimuli lead to extra risks at or below the targeted BMR, since they serve
as points of departure for an environmental risk assessment. The construction of a joint posterior
for ξ and γ0 allows for convenient exploration of features on the extra risk scale, by querying their
corresponding draws from the bivariate AM-chain.
3.5.1 Posterior extra risks at selected doses
Under our reparameterization, a one-to-one correspondence will typically exist between the
pair (γ0, ξ) and the RE(d) curve in the extra risk space. For example, with the quantal-linear
model the extra risk RE(d) = 1 − (1 − BMR)
d/ξ is clearly dependent upon ξ (and is independent
of γ0, although this is not guaranteed in general): as ξ increases, the quantal-linear RE(d) curve
becomes less concave and drops towards zero in a consistent fashion. Such correspondences allows
us to explore the posterior distribution of the extra risk at any given d, after obtaining the joint
posterior distribution of (γ0, ξ).
For example, a risk assessor may be interested in the posterior distribution of the extra risk at
certain crucial or regulatory dose levels. Given a posterior AM sample of (γ0, ξ) pairs, sans burn-
in, one can map these to the corresponding posterior sample of RE(d) curves. Then, the vertical
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intersection of this sample of curves at various dose levels d corresponds to a posterior sample of
the extra risk at that d. Density estimates of this posterior can be constructed via standard kernel
methods, allowing the analyst to compare the posterior densities across a variety of pertinent doses;
the latter could include the BMDL, the BMD estimate (or estimates, if different selection criteria
are under consideration), etc. We explore this possibility with the cumene data in §4.3, below.
3.5.2 Simultaneous credible bands
This correspondence between (γ0, ξ) pairs and RE(d) curves open up a panoply of inferences
on the extra risk scale. For instance, a posterior ‘point’ estimate of RE(d) corresponds to a point
estimate of (γ0, ξ). The simplest example would be calculation of the mean centroid (ξ¯, γ¯0) from
the retained AM chain, since it is a well-defined quantity. (Bivariate medians are not always
unambiguously defined. And, the sort of asymmetric interest described above for estimating the
BMD is not as crucial for estimating the extra risk. Thus a ‘central’ value such as a mean-based
centroid would be a reasonable default.) The curve in RE-space corresponding to (ξ¯, γ¯0) serves as
an estimator, RˆE(d), for the extra risk.
Further, a 1 − α simultaneous credible band can be constructed in a straightforward fashion.
Simply identify a central subset of the retained AM chain containing 100(1 − α)% of the (γ0, ξ)
pairs and sweep out the envelope in RE-space to which these points correspond.
Risk-analytic operations generally focus attention on strictly upper limits for the extra risk—
corresponding to lower limits on the BMD. This leads to one-sided, upper, credible bands, and
simplifies the band construction. Simply find the ‘smallest’ retained (γ0, ξ) AM-pair above which
100(1 − α)% of the AM-draws lie. The corresponding RE(d) curve will serve as an upper band
on the extra risk, valid simultaneously over all d ≥ 0. How to define ‘smallest’ is, of course, open
to consideration. As an initial proposal, we suggest recognizing γ0’s nuisance status and focusing
on how ξ varies throughout (γ0, ξ)-space: find the smallest value of ξ above which 100(1 − α)%
of the (γ0, ξ) AM-pairs lie. [One can view this as a horizontal supporting line—or a supporting
hyperplane for models with more than two parameters—separating the upper 100(1 − α)% of the
retained chain from the lower 100α% in the (γ0, ξ) plane.] In effect, this reduces attention to the
marginal posterior for ξ and isolates the (γ0, ξ) pair at ξ = ξ100BMR. The corresponding curve in
RE-space serves as the 1− α upper band.
4 Cumene Carcinogenicity Data, Revisited
4.1 Benchmark data analysis
We applied our Bayesian approach with the reparameterized quantal linear model to the cumene
carcinogenicity data in Example 1. Notice that the C9H12 exposure dose, d, is actually a concentra-
tion (in ppm) here, and so technically we will compute benchmark concentrations (BMCs) based
on the quantal carcinogenicity data. We operated with BMR set to the traditional level of 0.10
(U.S. EPA, 2012). Using input from domain experts, the prior elicitation was based on existing
background from the toxicological literature. Table 2 summarizes the elicited values. (Details are
given in the Supplemental Document.) The consequent prior distributions employed in the anal-
ysis were ξ ∼ IG(0.53, 0.13) and γ0 ∼ Beta(1.36, 12.31). We then applied our AM approach to
approximate the posterior for ξ and γ0. No ‘data failures’ or ‘algorithm failures’ were encountered.
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Table 2: Prior elicitation summary for cumene carcinogenicity data.
Parameter Lower quartile, Q1 Median, Q2 Prior parameters
ξ 90 ppm (0.18*) 250 ppm (0.50*) α = 0.53 β = 0.13
γ0 0.04 0.08 ψ = 1.86 ω = 12.31
* after scaling to unit interval
We instituted an AM chain size of 100, 000, from which our convergence diagnostic procedure
recommended an initial burn-in of 10, 000 draws. The remaining 90, 000 draws were then employed
as the posterior approximation for these data. Trace plots showed adequate mixing of the chain; see
the Supplemental Document. Figure 1 displays the corresponding histogram (with overlayed kernel
density estimate) for the ξ component. A unimodal and slightly right-skewed marginal posterior
distribution for ξ is indicated.
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Figure 1: Histogram and kernel density estimator for posterior approximation to ξ10 in Example
1. Dose scale (ξ) is standardized to unit length after dividing by the highest dose in the data set.
Figure 2 displays the estimated risk function Rˆ(d) based on the median posterior estimates for
(ξ, γ0), the lower tercile estimates for (ξ, γ0), and the MLEs (ξˆ, γˆ0), along with the original observed
proportions. All three curves give reasonable estimates for R(d), relative to the data, although the
median-based Bayesian estimate shifts consistently to the right of the other two risk functions at
most levels of d.
For reporting purposes, the final benchmark estimates (when translated back to the original
ppm scale) are ξˆ10=17.973 ppm if using the sample posterior median or ξˆ10=17.046 ppm if using
the sample posterior lower tercile. The 95% BMCL is ξ10 = 14.752 ppm. Comparing these to
standard frequentist estimates, the MLE is ξˆ10=17.062 ppm and a 95% frequentist Wald BMCL
is ξ10 = 13.618 ppm. Both sets of values rest in similar ranges, and provide comparable points of
departure for conducting further risk-analytic calculations on cumene carcinogenicity.
Thus for these data, our Bayesian approach operates similarly to the frequentist analysis, but
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Figure 2: Estimated risk functions for cumene carcinogenicity data in Example 1. Solid curve
( ) is based on the posterior median, dashed curve ( ) is based on the lower posterior
tercile, and dotted curve (· · · · · · ) is from the maximum likelihood estimate (MLE). The estimated
risk function based on the lower tercile is indistinguishable from the estimated ML risk function
at this scale. Solid circles are observed proportions. Dose scale (ξ) is standardized to unit length
after dividing by the highest dose in the data set.
it also provides an additional benefit for risk assessors: the Bayesian strategy combines elicited
prior information on both the background risk and the BMC, potentially improving the estimation
process by incorporating more-complete prior information.
4.2 Prior sensitivity
To explore sensitivity of the IG prior for these data, we returned to the methods in §3.4
and contaminated the base prior for ξ via three scenarios. In Scenario 1, we chose an objective
IG(0.001, 0.001) as the base prior for ξ and contaminated it by the similar, objective, Gamma(0.001,
0.001) prior. This scenario was used to investigate the sensitivity of the IG(0.001, 0.001) prior for
ξ100BMR when no elicitation is available. In Scenario 2, we chose the elicited IG prior as the base
prior for ξ and contaminated it by a similarly elicited gamma prior. We used the same quartile
information for ξ to build both elicited priors. Scenario 2 was used to investigate the sensitivity
of the IG prior when elicitation is available. In Scenario 3, we chose the elicited IG prior as the
base prior for ξ and contaminated it by an objective Gamma(0.001, 0.001) prior. Scenario 3 was
used to investigate the robustness of ξ100BMR when the elicited IG prior is contaminated by an
objective gamma prior. Throughout, the prior for γ0 was taken as either the elicited beta prior,
Beta(1.36, 12.31), or an objective Beta
(
1
2 ,
1
2
)
prior. This gave six different settings for study, under
which we monitored the consequent BMDL ξ100BMR(ǫ) as ǫ increased from 0 to 1. The corresponding
|D(q)| instantaneous change measures from (3.4) were also calculated.
Figure 3 displays the evolution of ξ100BMR(ǫ) across these six settings. The three choices for
ξ are distinguished using different line types (see the figure legend), and the two beta priors are
distinguished using grey or black shading. In Scenario 1, no substantive change in ξ100BMR(ǫ) is
evidenced as ǫ varies from 0 to 1 in Figure 3. This suggests that the objective IG(0.001, 0.001) prior
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is essentially equivalent to an alternative objective Gamma(0.001, 0.001) prior in approximating
the improper reciprocal prior, at least for these data. For either prior on γ0, the various ξ100BMR(ǫ)
values are also typically smaller than those from the other scenarios: the objective priors appear
to consistently shrink the BMDL towards zero.
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Figure 3: Kernel smoothed value of ξ10 as a function of changing ǫ in ǫ-contamination study with
cumene carcinogenicity data from Table 1. Solid curves ( ) are from Scenario 1: an objective
IG(0.001, 0.001) prior for ξ is contaminated by an objective Gamma(0.001, 0.001) prior. Dashed
curves ( ) are from Scenario 2: the elicited IG prior for ξ is contaminated by the elicited gamma
prior. Dotted curves (· · · · · · ) are from Scenario 3: the elicited IG prior for ξ is contaminated by an
objective Gamma(0.001, 0.001) prior. Gray curves indicate an objective Beta
(
1
2 ,
1
2
)
prior for γ0;
black curves indicate the elicited beta prior for γ0. Dose scale (ξ) is standardized to unit length
after dividing by the highest dose in the data set.
In Scenario 2, ξ100BMR(ǫ) decreases in an exponentially decaying fashion, to a maximum drop
of about 3 − 4% as ǫ increases from 0 to 1 (Figure 3). This smooth decrease suggests that the
contaminating gamma prior affects ξ100BMR in a consistent fashion as ǫ changes. However, the
relatively small maximum decrease also suggests that the sensitivity of ξ100BMR to the contaminating
elicited gamma is limited.
In Scenario 3, small decreases in ξ100BMR(ǫ) are evidenced as ǫ increases from 0 to approximately
0.8, followed by a precipitous drop as ǫ increases to 1 (Figure 3). The maximum decrease is slightly
more than 4%, however. This provides some evidence for the robustness of ξ100BMR under an elicited
IG prior; a significant amount of contamination from the objective prior is required to greatly reduce
the BMCL. In each scenario, we also see that these patterns occur for either form of prior for γ0,
although, on average, the elicited γ0 prior consistently produces a roughly 0.3% smaller BMCL
than the objective γ0 prior.
Table 3 gives the values for |D(q)| under each scenario. We also include a relative error,
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measuring the maximum change in ξ100BMR(ǫ) compared to ξ100BMR(0):
δ100BMR =
ξ100BMR(0) −min
{
ξ100BMR(ǫ)
}
ξ100BMR(0)
.
The relative errors for Scenario 1 are all less than 1%, suggesting little overall decrease in ξ100BMR
as ǫ increased from 0 to 1. For Scenarios 2 and 3, the relative errors are all approximately 4% (also
noted above). Although non-trivial, such small changes suggests only minor sensitivity of the base
priors to the contaminating priors, at least for these data. Values of |D(q)| for Scenario 1 and 3 are
all very close to 0, suggesting tiny instantaneous change of ξ100BMR at ǫ = 0. These are consistent
with the graphical patterns seen in Figure 3. By contrast, for Scenario 2 |D(q)| is roughly 1 to 3
orders of magnitudes higher than the other scenarios. This is again consistent with the patterns in
Figure 3.
Table 3: Relative errors, δ100BMR, and instantaneous change measure, |D(q)|, for each prior contam-
ination scenario (see text) with the cumene carcinogenicity data in Table 1.
Objective beta prior Elicited beta prior
Scenario δ100BMR |D(q)| δ100BMR |D(q)|
1 7.679× 10−3 1.134× 10−4 5.287× 10−3 5.632× 10−6
2 3.767× 10−2 1.905× 10−3 3.645× 10−2 1.839× 10−3
3 4.477× 10−2 4.536× 10−5 4.396× 10−2 4.174× 10−5
4.3 Posterior Extra Risks
The posterior extra risks are further compared, according to the description in §3.5.1. For a
comparison, we fix two crucial dose values: our 95% Bayesian BMCL of d = ξ10 = 14.752 ppm and
the frequentist 95% BMCL of d = ξ10 = 13.618 ppm. Figure 4 presents kernel density estimates of
the posterior extra risk at each d. Both density estimates appear roughly symmetric and lie fairly
close to each other. As expected, since it is taken at a higher level of dose, the posterior density
at the Bayesian BMCL locates farther up the extra risk scale: the mean extra risk at the Bayesian
BMCL is 0.083 while the mean extra risk at the frequentist BMCL is 0.077. This reiterates the
greater conservatism of the frequentist estimates with these data.
The standard deviation of the posterior extra risk at the Bayesian BMCL is 0.0096 while the
standard deviation of the posterior extra risk at the frequentist BMCL is 0.0090. Again, these
values are comparable; the frequentist BMCL is slightly less variable. The 95th percentile of the
extra risks at the Bayesian BMCL is exactly 0.1, as expected; the 95th percentile of the extra risks
at the frequentist BMCL is 0.093 which again illustrates the conservatism of the frequentist BMCL.
Figure 5 presents a 95% posterior credible band for the extra risk, using the method described
in §3.5.1. The centroid estimate for the extra risk is also included (dashed curve). By construction,
the corresponding dose level at BMR = 0.1 on the 95% band coincides with the Bayesian BMCL
obtained above.
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Figure 4: Kernel density estimators of posterior distribution for extra risk RE(d), where d is taken
as the Bayesian BMCL ( ) and as the frequentist BMCL ( ) in Example 1. Vertical bar
indicates the BMR at 0.10.
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Figure 5: 95% posterior credible band ( ) and centroid estimate ( ) for extra risk function
RE(d) in Example 1. Bayesian BMCL at BMR = 0.1 also marked, via inversion of the 95% band.
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5 Discussion
Herein, we consider a Bayesian approach for estimating benchmark doses (BMDs) in quanti-
tative risk analysis. Placing emphasis on environmental carcinogenicity assessment, our method
estimates the BMD via meaningfully reparameterized quantal-response models. Prior information
for the parameters is incorporated through an elicitation process, although use of objective pri-
ors is also considered. Due to the complexity of the reparameterized models, the joint posterior
distribution for the unknown parameters is approximated via Monte Carlo methods, using a com-
putationally intensive but stable adaptive Metropolis (AM) algorithm. A lower Bayesian credible
limit (BMDL) is estimated as the lower percentile of the AM sample. Environmental risk analysts
can employ this Bayesian approach to construct inferences on the BMD/BMDL by incorporating
expert prior knowledge for the model parameters.
Of course, some caveats and qualifications are in order. Objective prior specification can be
approached via many strategies when elicitation breaks down. We have assumed independent
IG(0.001, 0.001) and Beta
(
1
2 ,
1
2
)
priors for ξ and γ0, respectively. Other forms may be pertinent,
however, and we acknowledge the possible subjectivity that these choices bring to our model.
Another important issue concerns potential model uncertainty. Our representation for the risk
function was based on the popular quantal linear model. Many other forms, some quite complex, can
be chosen to model R(d), however. The logistic form R(d) = 1/(1+ e−β0−β1d) from §1.2 is a highly
popular alternative (Foronda et al., 2007; Shao and Small, 2012). Or, the quantal linear model can
be extended into a ‘two-stage’ model, R(d) = 1− exp(−β0−β1d−β2d
2), where βj ≥ 0 ∀j = 0, 1, 2.
Indeed, it is straightforward to employ our reparameterization strategy with both these models: all
aspects of the Bayesian estimation scheme in §3 remain valid, including our elicitation strategies
for the priors and the AM approach for building the joint posterior. [The three βjs in the two-stage
model require incorporation of an additional, reparameterized, nuisance parameter. Details are
given in Fang (2014).]
For instance, if we apply the logistic model to the cumene carcinogenicity data in Table 1, the
BMC estimates on the original ppm scale are ξˆ10=42.946 ppm (if using the sample posterior median)
or ξˆ10=40.892 ppm (if using the sample posterior lower tercile). The 95% BMCL is ξ10=35.599
ppm. These values contrast greatly with those from the quantal linear model in §4.1, leading one
to ask which is more appropriate—a classic example of model uncertainty. To compare the two
fits, we turn to the Bayes Factor (BF ) (Kass and Raftery, 1995): the BF comparing the quantal
linear model to the logistic model is calculated as the ratio of corresponding marginal likelihoods:
BF =
mql(Y )
mlo(Y )
, (5.1)
where mql(Y ) denotes the marginal likelihood using the quantal linear model and mlo(Y ) denotes
the marginal likelihood using the logistic model. We approximate both marginal likelihoods using
the geometric estimator and bridge sampling method from §3.4, producing BF = 518.3 for the
cumene data. Following Kass and Raftery (1995, §3.2), since this BF exceeds 150 we say there is
‘very strong’ evidence that the quantal linear model fits the data better than the logistic model.
(This is, perhaps, not surprising: the concave response observed in Figure 2 would be difficult for
a logistic model to match, compared to the always-concave quantal linear form.)
Clearly, model adequacy is an important issue in benchmark risk analysis (West et al., 2012). It
has received limited attention, however, particularly from a Bayesian perspective (Shao and Small,
2012). We are expanding our Bayesian BMD estimation approach to consider other popular quantal-
response models, and to deal with model adequacy concerns. We hope to report on this in a future
manuscript.
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Appendix
In this appendix we summarize the empirical screen employed to mark quantal data sets as
dose-response ‘data failures.’ Over increasing doses 0 = d1 < . . . < di < . . . < dm (i = 1, . . . m), we
first calculate the empirical extra risks:
R˜E(di) =
Yi
Ni
− Y1N1
1− Y1N1
.
We then connect each point
(
di, R˜E(di)
)
to the origin and find the largest slope, Smax, among all
these m−1 rays. If Smax ≤ 0, no increasing trend is evidenced and we mark this as a ‘data failure’.
Notice that we do not perform a formal trend test to detect a decreasing trend (Wheeler and Bailer,
2009a), but we do require that at least one estimated risk for some di (i > 1) is higher than the
estimated background risk.
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This supplementary document provides supporting material for Bayesian Benchmark Dose
Analysis by Qijun Fang and Walter W. Piegorsch (the ‘main document’). The various
sections below address a variety of supplemental/supporting topics, and are not intended to
flow naturally between each other. They are, however, presented in roughly the same order
in which their counterpart topics appear in the main document. As there, we denote the
Benchmark Dose (BMD) target parameter as ξ and the background response probability
nuisance parameter as R(0) = γ0.
1 Finding prior parameters from elicited quantiles
We give here technical aspects on derivation of the prior parameters α, β, ψ, and ω
for the prior densities ξ ∼ IG(α, β) and γ0 ∼ Beta(ψ, ω) used in the main document’s
hierarchical model. The elicited lower quartiles and medians Q1ξ, Q2ξ for ξ, and Q1γ , Q2γ for
γ0, respectively, are assumed given from domain expert(s) input.
Start with the elicitation for ξ: by definition, Q1ξ and Q2ξ satisfy∫ Qjξ
0
βα
Γ(α)
ξ(−α−1) exp
{
−
β
ξ
}
dξ =
j
4
,
(j = 1, 2), where the integrand is the IG p.d.f. This establishes a system of non-linear
equations for α and β. Unfortunately, no closed-form solution exists for the system, and so we
turn to numerical methods. We employ a gradient method discussed by Barzilai and Borwein
(1988) and implemented in the R statistical environment (R Development Core Team, 2012)
via the BB package (Varadhan and Gilbert, 2009). This method employs iterative updating
until half the L2 norm of the system at the proposed solution is smaller than 10
−10.
Similarly, for γ0 the elicited quartiles Q1γ and Q2γ satisfy∫ Qjγ
0
Γ(ψ + ω)
Γ(ψ)Γ(ω)
γψ−10 (1− γ0)
ω−1dγ0 =
j
4
,
(j = 1, 2), now applying the p.d.f. for the beta prior. Here again, the resulting system of
non-linear equations possesses no closed-form solution, so we appeal to the BB package in R.
The resulting iterative solutions to these two systems of equations produce values for the
prior parameters α, β, ψ, and ω which are then employed in our hierarchical model for the
BMD.
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2 The adaptive Metropolis algorithm
The posterior p.d.f. under our hierarchical model is
π(ξ, γ0|Y ) =
f(Y |ξ, γ0)π(ξ|α, β)π(γ0|ψ, ω)
m(Y )
(2.1)
=
∏n
i=1R(di)
Yi[1− R(di)]
Ni−Yi
m(Y )
βαe−β/ξ
Γ(α)ξα+1
Γ(ψ + ω)
Γ(ψ)Γ(ω)
γψ−10 (1− γ0)
ω−1,
where
m(Y ) =
∫ ∞
0
∫ 1
0
f(Y |ξ, γ0)π(ξ|α, β)π(γ0|ψ, ω)dγ0dξ.
By employing proper priors, this is guaranteed to be integrable (Gelman et al., 2004, §5.3),
which helps motivate our preference for the IG and beta prior assumptions on ξ and γ0,
respectively. Nonetheless, the posterior is intractable, so we turn to approximation by com-
puter. Markov chain Monte Carlo (McMC) approaches have been applied with great success
to models such as this (Robert and Casella, 2011), although the complexity of (2.1) prevents
us from applying well-known McMC algorithms such as Gibbs sampling (Gelfand, 2000). In-
stead, we move to Metropolis-Hastings approaches (Robert and Casella, 2004, Ch. 7) and
in particular consider adaptive Metropolis (AM) algorithms. These tune the variance of the
underlying Metropolis proposal density adaptively when generating ongoing draws of the
chain. From our experience with a variety of such methods, we favor a global AM procedure
with componentwise adaptive scaling described by Andrieu and Thoms (2008). Their ‘AM6’
algorithm uses all previous iterations in the chain to update the variance-covariance matrix
of the current bivariate proposal density. The operation is global in the sense that both the
ξ and γ0 parameters are updated simultaneously at each kth bivariate draw; k = 1, . . . , K.
It is also componentwise in the sense that the updating step sizes for ξ and γ0 are controlled
by separate adaptive scaling parameters. See Andrieu and Thoms (2008) for further details.
To begin the AM chain, ‘starting’ points for ξ and γ0 must be chosen. Rather than ap-
plying a random initialization, we take the starting point for γ0 as
Y1+0.25
N1+0.5
, i.e., the estimated
nonresponse probability with a slight shrinkage term included to pull away from the zero
boundary.
The starting point for ξ was obtained by first treating RE(d) = Smaxd as an empirical
approximation to the extra risk function and then solving for d in the equation BMR =
Smaxd. Here, Smax is the maximum empirical origin-to-response slope described in the main
document’s Appendix. We then find the starting point for ξ as simply BMR/Smax.
The AM6 algorithm employs a bivariate normal proposal distribution. Andrieu and Thoms
(2008) recommend 2.38
2
2
I as an initial variance-covariance matrix, where I is the 2×2 identity
matrix. At each subsequent iteration, the variance-covariance matrix of the normal proposal
density is then updated based on the previous iteration’s variance-covariance matrix and on
the current iteration’s adaptive scaling parameters for ξ and γ0. See Andrieu and Thoms
(2008) for details.
2
3 Monte Carlo ‘burn-in’ diagnostics
To account for potential instability in the early portions of the bivariate chain, we include
a ‘burn-in’ for the Monte Carlo sample (Gelman et al., 2004, §11.6). We couple this with
the larger question of how to assess the chain’s convergence. Many approaches exist for
diagnosing McMC convergence (Cowles and Carlin, 1996), and indeed, the issue is a topic
of ongoing debate (Robert and Casella, 2004, §12.2). We mimic a method due to Geweke
(1992), where early portions of the chain are sub-sampled and compared against latter por-
tions to determine where the larger sample of K draws begins to exhibit stable performance.
To approximate independence between the two sub-samples, we bifurcate the chain by a gap
of no less than K
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consecutive draws.
For summary diagnostics, we calculate the difference in arithmetic means between the
two bifurcated sub-samples, and divide each difference by its standard error to produce
a Z-statistic. The approximate standard error is taken as the square root of the sum of
the variances of each mean. This is done separately for both the ξk and γ0k components,
k = 1, . . . , K. (For sake of simplicity, we make no correction for multiplicity.) To adjust
for possible autocorrelation within each sub-sample, the individual variances are based on
estimated spectral densities at frequency zero; see Fang (2013) for full details.
To monitor if the pattern of association between ξ and γ0 within the larger chain also
exhibits reasonable stability, we include comparison of the covariances between the two sub-
samples. As a diagnostic measure here we use the sample covariance from each sub-sample,
Ĉov(ξ, γ0) =
1
L
L∑
k=1
(ξk − ξ¯)(γ0k − γ¯0),
where ξ¯ and γ¯0 are the pertinent arithmetic means within a bifurcated sub-sample of length
L. To find the approximate variance of each estimated covariance we calculate the quantities
ψk = (ξk − ξ¯)(γ0k − γ¯0) across all values of k in the given sub-sample and then estimate the
variance of ψk based on their estimated spectral densities at frequency zero.
Each such comparison is conducted over three individual, separated bifurcations of the
full K-length sample: (i) the first 10% of the chain (L = K/10) vs. the final 50% (L = K/2);
(ii) the first 20% of the chain (L = K/5) vs. the final 50%; and (iii) the first 30% of the chain
(L = 0.3K) vs. the final 50%. We consider an individual diagnostic comparison as a ‘pass’
if the corresponding Z-statistic comparing the two bifurcated samples is less than 1.96 in
absolute value. To ‘pass’ the full diagnostic at each bifurcation, all three measures—mean
of ξ, mean of γ0, and covariance of {ξ,γ0}—must individually pass.
The comparisons are performed in sequential order: if the 10%-vs.-50% diagnostic fails,
then the 20%-vs.-50% diagnostic is conducted. If this fails, we move to the 30%-vs.-50%
diagnostic. When a diagnostic passes, we view the indicated early portion of the chain as
a reasonable burn-in. For notation, we let K0 < K be the resulting index that begins the
retained portion of the chain. So, e.g., if the 10%-vs.-50% diagnostic fails but then the
20%-vs.-50% diagnostic passes, we take the first 20% of the chain as burn-in and use the
remaining 80% of the chain as our Monte Carlo sample from π(ξ, γ0|Y ). If K = 100, 000, as
used throughout, this gives K0 = 20, 001.
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If none of the three sequential diagnostics passes, we re-set the random-number gener-
ator’s seed and reassess a new set of K Monte Carlo draws. If after five such re-starts the
diagnostic continues to fail, we report an algorithm failure. (This did not occur very often;
see the simulation results in §6, below.)
4 Estimating marginals via bridge sampling
In the main document, we often have reason to calculate (an approximation to) a marginal
likelihood of the form
m(Y ) =
∫ ∞
0
∫ 1
0
f(Y |ξ, γ0)π(ξ|α, β)π(γ0|ψ, ω)dγ0dξ
for various choices of π(ξ|α, β) and/or π(γ0|ψ, ω). To do so, we construct a geometric es-
timator from our AM sample, appealing to the ‘bridge sampling’ method recommended by
Meng and Wong (1996) and Lopes and West (2004). To approximate the marginal likeli-
hood, an approximation g(·) to the joint posterior density of (ξ, γ0) is first chosen. For
simplicity, we took g(ξ, γ0) as the bivariate normal density function with mean set to the
empirical mean vector and variance set to the empirical variance-covariance matrix of ξ and
γ0 estimated from the AM sample. Next, a set of K
∗ = K − K0 + 1 bivariate vectors{
[ξ∗j γ
∗
0j ]
T
}K∗
j=1
are drawn from g(ξ, γ0). The marginal likelihood is then approximated by
substituting the (retained) AM sample,
{
[ξk, γ0k]
T
}K
k=K0
, and the generated sample from
g(ξ, γ0),
{
[ξ∗j γ
∗
0j]
T
}K∗
j=1
, into the ratio
m̂(Y ) =
1
K∗
∑K∗
j=1
{
π
(
ξ∗j |α, β
)
π
(
γ∗0j|ψ, ω
)
f
(
Y |ξ∗j , γ
∗
0j
)
/g
(
ξ∗j , γ
∗
0j
)}1/2
1
K∗
∑K
k=K0
[g (ξk, γ0k) / {π (ξk|α, β)π (γ0k|ψ, ω) f (Y |ξk, γ0k)}]
1/2
,
where f(·) denotes the binomial likelihood function and π(·) denotes the pertinent prior
density [e.g., q(ξ) when approximating mq(Y ) in our ǫ-contamination study].
5 Prior elicitation with the cumene data
To elicit the prior parameters for the cumene data in Example 1, we applied input from
domain experts and based the prior elicitation on existing background from the toxicological
literature. We began with the BMD target parameter, ξ: an oral No Observed Adverse Effect
Level (NOAEL) for long-term cumene exposure in rodents was given by the EPA IRIS website
(http://www.epa.gov/iris/subst/0306.htm) as 110 mg/kg-day. Guidance for converting
the oral mg/kg-day metric to inhalation ppm (the scale used in the original data table
from the main document) was available via conversion data given by the California OEHHA
(2004): for rodents, 1 mg/kg-day works out to roughly 2.25 ppm. Arguing that a NOAEL is
loosely equivalent to a BMD—although, see (Kodell, 2005) for an in-depth discussion—the
median prior estimate was Q2ξ = 110 mg/kg-day = 247.5 ppm ≈ 250 ppm. For the first
quartile, the EPA IRIS site gave a cumene inhalation NOAEL for rodents as 435 mg/cu.m,
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based on a shorter, 13-week study. The shorter exposure period was suited to provide only a
limited estimate on the BMD’s central tendency; we translated this to use the 435 mg/cu.m
13-week NOAEL as a prior estimate of the first quantile. For conversion to inhalation ppm,
the EPA indicated that roughly 1 mg/cu.m = 0.204 ppm, so we took Q1ξ = 435 mg/cu.m =
88.75 ppm ≈ 90 ppm. We then divided the ppm dose by 500 ppm to standardize the ξ-scale
to 0 ≤ ξ ≤ 1. This produced prior first quartile and median estimates for π(ξ|α, β) as 0.18
and 0.5, respectively.
For γ0, historical control data on alveolar/bronchiolar tumors in B6C3F1 mice were given
by U.S. NTP (2009, Table D3a). These provide direct prior information on the background
risk. The historical data gave a median background response of Q2γ = 0.08 and a lower
quartile of Q1γ = 0.04.
These quartile-based elicitations were then used to construct the prior densities ξ ∼
IG(α, β) and γ0 ∼ Beta(ψ, ω) as described in §1, above.
6 Trace plot and convergence diagnostics for cumene
example
In the cumene example, an AM approach was applied to approximate the posterior for
ξ and γ0. At an initial chain size of 100, 000, Figure 1 displays the full trace plot for the ξ
component of this AM sample. The plot exhibits stable performance and fairly fast mixing.
Our convergence diagnostic procedure recommended an initial burn-in of 10, 000 draws. The
remaining 90, 000 draws were then used as the posterior approximation for these data.
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Figure 1: Trace plot for ξ in Example 1. Dose scale (ξ) is standardized to unit length after
dividing by the highest dose in the data set. First 10,000 Monte Carlo draws in grey indicate
burn-in period.
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